Cytek Biosciences Reports Q1 2025 Financial Results

Cytek Biosciences, Inc. ( (CTKB) ) has released its Q1 earnings. Here is a breakdown of the information Cytek Biosciences, Inc. presented to its investors.

Cytek Biosciences, Inc., headquartered in Fremont, California, is a leading company in the cell analysis solutions sector, known for its high-resolution and high-sensitivity cell analysis tools utilizing patented Full Spectrum Profiling technology.

In the first quarter of 2025, Cytek Biosciences reported a total revenue of $41.5 million, marking a 7.6% decrease compared to the same period in 2024. Despite this decline, the company expanded its installed base and launched a new product, the Cytek Muse Micro instrument, while also commencing operations in Singapore to enhance manufacturing capabilities.

Key financial metrics for the quarter include a gross profit of $20.2 million, a 12% decrease from the previous year, and a net loss of $11.4 million, compared to a $6.2 million net loss in the first quarter of 2024. Operating expenses increased by 4.1%, with significant spending in general and administrative expenses. The company also repurchased $10.6 million of its common stock during the quarter.

Looking forward, Cytek Biosciences remains optimistic about its strategic positioning, with plans to drive recurring revenue growth through its expanding installed base and global diversification. The company has revised its 2025 revenue guidance to a range of $196 million to $210 million, reflecting a potential growth of -2% to 5% over the previous year.